ArticleBMC infectious diseases2020
Factors associated with high-risk low-level viremia leading to virologic failure: 16-year retrospective study of a Chinese antiretroviral therapy cohort.
Article in BMC infectious diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 2 syntheses or guidelines pooled it, 64 citations in OpenAlex.
- Prevalence of low-level viremia and related influencing factors among people living with HIV in China: a systematic review and meta-analysis.Frontiers in public health · 2025Pooled it
- Burden of virologic failure, and its determinants among HIV positive children in East Africa: a systematic review and meta-analysis.African health sciences · 2024Pooled it
- Effectiveness of intensive adherence counselling in achieving an undetectable viral load among people on antiretroviral therapy with low-level viraemia in Uganda.HIV medicine · 2024Trial
- Decoding HIV-1 Next Move Through Matrix Protein p17 Quasi-Species.MicrobiologyOpen · 2026Article
- Characterization of drug resistance mutations in people living with HIV with low-level viremia on antiretroviral therapy in Chongqing, China.Frontiers in public health · 2026Article
- Factors associated with low-level viremia in people living with HIV: A 10-year retrospective study in South Korea.PloS one · 2026Article
- Low-level viremia and subsequent virologic failure among people living with HIV: a retrospective cohort study in China.BMC infectious diseases · 2025Article
- Higher levels of cell-associated HIV-1 RNA transcripts predict risk of viral blips: implications for clinical management and cure research.AIDS (London, England) · 2025Article
- A Guide to the Evolving Clinical Landscape of Low-Level Viremia Among Persons with HIV in the Modern Treatment Era.Current HIV/AIDS reports · 2025Review
- Cryo-EM Structure of HIV-1 Reverse Transcriptase withACS infectious diseases · 2025Article
- Association of HIV low-level viremia with CD4 count recovery among persons living with HIV during antiretroviral therapy in Dehong Prefecture, Southwest China in 2008-2021: a longitudinal study.BMC infectious diseases · 2025Article
- Transient Viremia Among People with HIV Receiving Injectable Cabotegravir Plus Rilpivirine.AIDS research and human retroviruses · 2025Article
- HIV Low-Level Viremia is Not Related to Subsequent Virological Failure Under NNRTI-Based Regimens: A Multicenter Retrospective Study in China.Infection and drug resistance · 2025Article
- Low-Level Viremia as an Independent Risk Factor for Metabolic Syndrome in People Living with HIV Receiving Antiretroviral Therapy: A 6-Year Retrospective Cohort Study.Infection and drug resistance · 2025Article
- Risk Factors Associated with Virological Failure in HIV Patients with Low Level Viremia: A Retrospective Study.Infection and drug resistance · 2025Article
- Prevalence of low-level viremia in people living with HIV/AIDS and its impact on virological failure in Guizhou Province, China.Frontiers in public health · 2025Article
- Characteristics of drug resistance mutations in ART-experienced HIV-1 patients with low-level viremia in Zhengzhou City, China.Scientific reports · 2024Article
- Low-level viremia episodes appear to affect the provirus composition of the circulating cellular HIV reservoir during antiretroviral therapy.Frontiers in microbiology · 2024Article
- Observational
- Risk factors and clinical prediction models for low-level viremia in people living with HIV receiving antiretroviral therapy: an 11-year retrospective study.Frontiers in microbiology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundLow level viremia (LLV) often occurs during antiretroviral therapy (ART) against HIV-1. However, whether LLV increases the risk of virologic failure (VF) is controversial because of the non-uniform definitions of LLV and VF.
methodsA long-term first line regimen ART cohort from 2002 to 2018 from Shenyang, northeast China, was retrospectively studied. All participants were followed up every 3 to 6 months to evaluate the treatment effect. The high-risk LLV subgroups leading to VF (with strict standards) were explored with Cox proportional hazards model and linear mixed-effect model. The association factors of high-risk LLV were further explored using multivariate logistic regression analyses.
resultsA total of 2155 HIV-1 infected participants were included; of these, 38.7% showed LLV. Both high level LLV (HLLV) and any other level LLV coupled with high level blip (HLB) showed higher risk of VF (hazards ratios, HR
conclusionsIn case of VF with strict standards, high-risk LLV leading to VF includes VL above 400 copies/ml, occurring at least once. Serious laboratory indicators or advanced stage of infection, long term ART and subtype B' infection might also predict the occurrence of high-risk LLV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.